

**Treating HCV in a Primary Care Setting Pat 1 & 2**

**Reference Page 4/23/21 & 4/30/21**

Rein et al. Dig Liver Dis 2011;43:66-72. Zalesak et al. PLOS ONE 2013;8(5):e63959

NIH Consens State Sci Statements. 2002;19(3):1-46.

Sene et al. Metab Brain Dis. 2004;19)3-4):357-381

Package prescribing insert : MAVYRET® (glecaprevir and pibrentasvir) tablets, for oral use Initial U.S. Approval: 2017

Package prescribing insert: EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use Initial U.S. Approval: 2016

Package prescribing insert: VOSEVI® (sofosbuvir, velpatasvir, and voxilaprevir) tablets, for oral use Initial U.S. Approval: 2017

Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and National Viral Hepatitis Roundtable (NVHR). 2017. https://stateofhepc.org/. Accessed August 2, 2018.